Clinical Trial Evidence: What the Research Shows
Mounjaro or Wegovy for Weight Loss: Understanding the Clinical Evidence
When evaluating Mounjaro or Wegovy for weight loss, the clinical trial data provides compelling evidence for both approaches, though direct comparisons remain limited due to different trial designs and populations. Wegovy's evidence base stems from the comprehensive STEP clinical programme, whilst Mounjaro's weight loss data emerges from the SURMOUNT trials. In clinical trials, patients taking Wegovy alongside diet and exercise achieved an average weight loss of approximately 15% at 68 weeks in the landmark STEP 1 study (Wilding et al., NEJM, 2021). The STEP 3 trial demonstrated even higher results of ~16% when combined with intensive behavioural therapy, whilst STEP 5 showed sustained weight loss of ~15.2% maintained over 2 years.
Mounjaro's clinical evidence presents a different mechanism of action, working as a dual GIP and GLP-1 receptor agonist compared to Wegovy's singular GLP-1 approach. Both treatments require prescription-only medicine status and must be used alongside a reduced-calorie diet and increased physical activity. The decision between these options involves understanding not just efficacy data, but practical considerations including dosing schedules, storage requirements, and individual response patterns that qualified prescribers can evaluate through comprehensive clinical assessment.
Wegovy and Mounjaro Pricing: Complete UK Cost Breakdown
Understanding the financial commitment for Mounjaro or Wegovy for weight loss requires transparency about UK prescription costs and available support options. Wegovy pricing at EverydayMeds starts with the 0.25mg starter dose at £79.99, progressing through 0.5mg (£94.99), 1mg (£99.99), 1.7mg (£139.99), to the maintenance 2.4mg dose at £209.99. New customers benefit from code FIRST40 applied at checkout, whilst returning customers use DOSE25 to reach these final prices. Our bundle options provide convenient multi-month supplies, such as the Intro Duo (0.25mg & 0.5mg) for £169.99 or the Progress Trio covering three dose escalations for £299.99.
Mounjaro pricing follows a different structure reflecting its distinct dosing protocol and dual-hormone mechanism. Both treatments represent significant investment in long-term weight management, requiring ongoing commitment beyond initial prescription costs. The choice between these prescription-only medicines shouldn't be driven by price alone, but by clinical suitability determined through proper medical assessment. EverydayMeds provides both options with identical service standards including 3-minute online assessments, prescriber review within 3 working days (24 hours express option), and next-day temperature-controlled delivery once approved.
STEP Trial Results: Wegovy's Clinical Weight Loss Evidence
The STEP clinical programme provides robust evidence for patients considering Mounjaro or Wegovy for weight loss, establishing Wegovy's efficacy across diverse populations and timeframes. STEP 1, the pivotal 68-week trial, demonstrated that patients taking Wegovy alongside lifestyle interventions achieved approximately 15% average weight loss compared to 2.4% with placebo (Wilding et al., NEJM, 2021). STEP 2 specifically examined patients with type 2 diabetes, showing ~9.6% weight reduction in this more challenging population.
The SELECT cardiovascular outcomes trial added crucial safety data, demonstrating a 20% reduction in major cardiovascular events (hazard ratio 0.80) amongst participants. However, STEP 1 extension data revealed that patients regained approximately two-thirds of weight lost within one year of stopping treatment, emphasising that weight management represents a long-term commitment rather than short-term intervention.
Mechanism Differences: How Wegovy and Mounjaro Work
Understanding the fundamental mechanisms distinguishes the choice between Mounjaro or Wegovy for weight loss beyond simple efficacy comparisons. Wegovy (semaglutide) operates as a selective GLP-1 receptor agonist, mimicking the natural incretin hormone that signals satiety to brain appetite centres. This mechanism reduces appetite, promotes feelings of fullness after smaller meals, and may diminish food cravings through direct action on hypothalamic appetite regulation pathways. Mounjaro (tirzepatide) employs a dual-hormone approach, targeting both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors simultaneously. This dual action potentially offers enhanced glucose regulation alongside appetite suppression, though both treatments require prescription-only medicine status due to their potent physiological effects.
EverydayMeds Ordering Process: From Assessment to Delivery
Accessing either option for Mounjaro or Wegovy for weight loss through EverydayMeds follows a streamlined yet thorough clinical pathway designed to ensure appropriate prescribing and patient safety. The process begins with a comprehensive 3-minute online clinical assessment covering medical history, current medications, weight management goals, and contraindication screening. Qualified prescribers review applications within standard 3 working days, with express 24-hour review available for urgent requirements. Once approved, next-day delivery utilises specialist cold-chain logistics maintaining the 2-8°C temperature requirements essential for medication stability. Our GPhC-registered pharmacy (#9012878) ensures full regulatory compliance whilst providing accessible weight management solutions across the UK.
Storage and Practical Considerations for Weight Loss Treatments
Practical storage differences significantly impact the real-world choice between Mounjaro or Wegovy for weight loss, particularly for patients with active lifestyles or frequent travel requirements. Wegovy demonstrates superior temperature stability, remaining effective for up to 6 weeks at room temperature below 30°C once removed from refrigerated storage, compared to Mounjaro's 21-day room temperature limit. Both treatments require initial refrigerated storage at 2-8°C and utilise pre-filled FlexTouch injection pens for convenient once-weekly administration. Dose escalation protocols differ between treatments, with Wegovy following a structured 16-week escalation from 0.25mg to maintenance 2.4mg, whilst Mounjaro employs its own titration schedule. Neither treatment should be frozen, and both require disposal through appropriate pharmaceutical waste channels after use.
UK Weight Loss Results: Real-World Clinical Outcomes
Evaluating real-world UK outcomes for Mounjaro or Wegovy for weight loss extends beyond controlled trial environments to practical NHS and private healthcare settings. UK prescribing data through specialist weight management services increasingly reflects the clinical trial evidence, with patients achieving meaningful weight loss when treatments are combined with comprehensive lifestyle support. NICE guidance TA875 specifically recommends Wegovy alongside specialist weight management programmes, recognising the importance of holistic approaches rather than medication alone.
Both treatments require ongoing monitoring through qualified healthcare providers, with regular assessment of efficacy, tolerability, and cardiovascular risk factors. UK patients accessing these prescription-only medicines through private providers like EverydayMeds benefit from continued prescriber support throughout their weight management journey. The choice between treatments often depends on individual response patterns, tolerability profiles, and practical considerations that emerge during real-world use rather than theoretical clinical trial scenarios.
Making Your Decision: Expert Prescriber Guidance Available
The ultimate choice between Mounjaro or Wegovy for weight loss shouldn't be made in isolation but through collaborative decision-making with qualified healthcare professionals who understand both treatments' nuanced benefits and limitations. EverydayMeds prescribers evaluate individual medical histories, concurrent medications, weight loss goals, lifestyle factors, and practical considerations to recommend the most appropriate option. Both treatments are available through our platform with identical service standards, ensuring that clinical suitability rather than availability drives treatment selection. New customers can begin their assessment using code FIRST40, whilst returning patients benefit from DOSE25 applied at checkout to access these innovative weight management solutions. Start your clinical assessment today through https://everydaymeds.co.uk/collections/wegovy to explore which option aligns with your specific circumstances and health goals.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
